These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 19358672

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
    Espinel-Ingroff A, Johnson E, Hockey H, Troke P.
    J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.
    Lamaris GA, Ben-Ami R, Lewis RE, Kontoyiannis DP.
    J Antimicrob Chemother; 2008 Sep; 62(3):539-42. PubMed ID: 18544603
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis.
    Chamilos G, Lewis RE, Hu J, Xiao L, Zal T, Gilliet M, Halder G, Kontoyiannis DP.
    Proc Natl Acad Sci U S A; 2008 Jul 08; 105(27):9367-72. PubMed ID: 18583479
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD, Kiraz N.
    Mycoses; 2007 Nov 08; 50(6):447-50. PubMed ID: 17944704
    [Abstract] [Full Text] [Related]

  • 12. Post-antifungal effect of amphotericin B and voriconazole against germinated Aspergillus fumigatus conidia.
    Chryssanthou E, Loebig A, Sjölin J.
    J Antimicrob Chemother; 2008 Jun 08; 61(6):1309-11. PubMed ID: 18367461
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
    Spreghini E, Orlando F, Giannini D, Barchiesi F.
    J Antimicrob Chemother; 2010 Oct 08; 65(10):2158-63. PubMed ID: 20667887
    [Abstract] [Full Text] [Related]

  • 14. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP.
    Diagn Microbiol Infect Dis; 2005 May 08; 52(1):15-20. PubMed ID: 15878437
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
    Bellanger AP, Albert ND, Lewis RE, Walsh TJ, Kontoyiannis DP.
    Antimicrob Agents Chemother; 2015 Dec 08; 59(12):7830-2. PubMed ID: 26392499
    [Abstract] [Full Text] [Related]

  • 17. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.
    Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA.
    Clin Infect Dis; 2004 Sep 01; 39(5):743-6. PubMed ID: 15356792
    [Abstract] [Full Text] [Related]

  • 18. Activity of posaconazole in treatment of experimental disseminated zygomycosis.
    Dannaoui E, Meis JF, Loebenberg D, Verweij PE.
    Antimicrob Agents Chemother; 2003 Nov 01; 47(11):3647-50. PubMed ID: 14576138
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.